Omaxe Limited , in a regulatory filing dated May 15, 2026, informed the stock exchanges that its Board of Directors approved key auditor appointments at its board meeting held on the same date. The disclosures were made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

Auditor Appointments at a Glance

The Board approved two appointments and noted one cessation, all effective May 15, 2026. The following table summarises the key changes:

Profile of Newly Appointed Cost Auditors

M/s S.K. Bhatt & Associates is a Cost Accountancy firm with more than 27 years of professional experience. The firm offers a broad range of services, including:

• Management Consultancy and GST Consultancy
• Tax matters and Cost Accounting Services
• Corporate law matters and Insolvency-related matters
• NCLT/NCLAT case filing and appearances
• Project finance and setting up projects on a turnkey basis
• Secretarial Services

The firm is professionally managed and comprises distinguished Cost Accountants, Corporate Financial Advisors, and Tax Consultants. Its team maintains regular interaction with industry and other professionals to stay current with contemporary developments.

Profile of Newly Appointed Internal Auditors

M/s Aditya V Agarwal & Company, Chartered Accountants, brings over 8 years of professional experience in audit, taxation, accounting, due diligence, CFO advisory, and compliance services. The firm serves more than 150 Indian clients and 25+ international clients across diverse industries and geographies, including the USA, Canada, Saudi Arabia, Singapore, and Vietnam. Supported by a team of 32 qualified professionals, the firm also possesses significant expertise in startup advisory, financial due diligence, and fundraising support.

Regulatory Compliance and Disclosure

The intimation was signed by D B R Srikanta, Company Secretary and Compliance Officer of Omaxe Limited, and has been made available on the company's website at www.omaxe.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited. The filing confirms full compliance with the applicable SEBI disclosure requirements for changes in auditor appointments.

Omaxe Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following the Board of Directors meeting held on May 15, 2026. The results, approved under Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveal a widening net loss and a significant decline in revenue on a year-on-year basis across both standalone and consolidated financials. Statutory auditor M/s B S D & Co., Chartered Accountants (FRN: 000312S), issued unmodified audit opinions on both the standalone and consolidated financial results. The results were subsequently published in Business Standard (English and Hindi) on May 15, 2026, in compliance with Regulation 47 of the SEBI LODR Regulations, 2015.

Q4 FY26 and Full-Year Financial Performance

Omaxe's consolidated financials for Q4 FY26 showed deterioration across key metrics compared to the same period last year. On a consolidated basis, revenue from operations for Q4 FY26 declined to ₹348.52 Cr from ₹541.26 Cr in Q4 FY25. The consolidated net loss after tax for Q4 FY26 stood at ₹191.42 Cr, compared to ₹148.67 Cr in Q4 FY25. For the full year FY26, consolidated revenue from operations stood at ₹1,253.40 Cr, down from ₹1,560.99 Cr in FY25, while the consolidated net loss after tax widened to ₹696.80 Cr from ₹685.40 Cr in FY25.

The table below summarises the key consolidated financial highlights:

Standalone Financial Performance

On a standalone basis, Omaxe's Q4 FY26 total income rose to ₹168.49 Cr from ₹150.47 Cr in Q4 FY25. However, the standalone net loss after tax for Q4 FY26 widened significantly to ₹83.05 Cr from ₹20.76 Cr in Q4 FY25, driven by a sharp increase in total expenses to ₹278.81 Cr from ₹170.35 Cr. For the full year FY26, standalone total income grew to ₹514.67 Cr from ₹449.97 Cr in FY25, while the standalone net loss after tax narrowed to ₹195.61 Cr from ₹217.03 Cr in FY25.

Balance Sheet and Cash Flow Highlights

As of March 31, 2026, Omaxe's consolidated total assets stood at ₹16,522.32 Cr, up from ₹14,877.41 Cr as of March 31, 2025, driven primarily by a significant increase in consolidated inventories to ₹12,315.85 Cr from ₹10,997.66 Cr. Consolidated cash and cash equivalents improved to ₹490.38 Cr from ₹300.93 Cr. On the liabilities side, consolidated non-current borrowings rose sharply to ₹1,267.07 Cr from ₹499.24 Cr, while consolidated other equity turned more negative at ₹(1,084.42) Cr compared to ₹(388.03) Cr in the prior year. On a standalone basis, total assets grew to ₹6,829.84 Cr from ₹6,290.30 Cr, with standalone cash and cash equivalents improving to ₹128.54 Cr from ₹25.20 Cr.

From a cash flow perspective, consolidated net cash generated from operating activities for FY26 stood at ₹211.99 Cr, compared to ₹1,006.67 Cr in FY25. Standalone net cash from operating activities was ₹426.82 Cr versus ₹585.32 Cr in FY25.

Board Decisions and Auditor Appointments

At the Board meeting held on May 15, 2026, in addition to approving the financial results, the Board also approved the appointment of M/s S.K. Bhatt & Associates, Cost Accountants, as Cost Auditors for FY26-27, and the appointment of M/s Aditya V Agarwal & Company, Chartered Accountants, as Internal Auditors for FY26-27, replacing M/s Doogar & Associates, who resigned due to pre-occupation with other assignments. Both new appointments are effective May 15, 2026. The Board also noted proposed final dividends from certain wholly owned subsidiaries, subject to approval at their respective general meetings, as detailed below:

Regulatory and Legal Disclosures

The auditors drew attention to an ongoing regulatory matter in their Emphasis of Matter paragraph. Omaxe had received an order dated July 30, 2024, from SEBI under sections 11 and 11B of the SEBI Act, 1992, covering the period from FY2018-19 to FY2020-21. The company filed an appeal with the Securities Appellate Tribunal (SAT), which granted a stay on directions at para 41(i) of the SEBI order vide its order dated October 1, 2024. The next date of hearing before SAT is July 7, 2026. The management has stated that the said order has no impact on the financial results of the company. Separately, Omaxe confirmed that as of March 31, 2026, it does not qualify as a "Large Corporate" under the relevant SEBI circulars on fund raising by issuance of debt securities. The company's outstanding qualified borrowings stood at ₹414.08 Cr at year-end, up from ₹178.39 Cr at the start of the financial year, with incremental borrowings of ₹200 Cr and debt securities issuance of ₹63.30 Cr during the year. The company holds a credit rating of ACUITE BBB- (Stable) from Acuite Ratings & Research Limited.